Sanofi says its Aubagio significantly slowed brain atrophy in relapsing multiple sclerosis in late-stage trial

7 October 2015

French drug major Sanofi (Euronext: SAN) along with its unit Genzyme on Wednesday said a late-stage trial for its drug to treat relapsing multiple sclerosis (RMS) showed it significantly slowed brain volume loss.

The company is conducting Phase III trials for its Aubagio (teriflunomide).

Bill Sibold, head of Genzyme's multiple sclerosis business, said: "These results showing the reduction in brain atrophy over two years add to the growing body of data for Aubagio. We remain committed to furthering the understanding of Aubagio and the potential benefits it could deliver to relapsing MS patients."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK